Literature DB >> 33787921

On the Quest of Risk Stratification in HER2-Positive Breast Cancer.

Mei-Yin C Polley1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 33787921      PMCID： PMC8902343          DOI： 10.1093/jnci/djab061

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  9 in total

Review 1.  Biomarker: Predictive or Prognostic?

Authors:  Karla V Ballman
Journal:  J Clin Oncol       Date:  2015-09-21       Impact factor: 44.544

2.  Statistical and practical considerations for clinical evaluation of predictive biomarkers.

Authors:  Mei-Yin C Polley; Boris Freidlin; Edward L Korn; Barbara A Conley; Jeffrey S Abrams; Lisa M McShane
Journal:  J Natl Cancer Inst       Date:  2013-10-17       Impact factor: 13.506

3.  Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.

Authors:  Kristine R Broglio; Melanie Quintana; Margaret Foster; Melissa Olinger; Anna McGlothlin; Scott M Berry; Jean-François Boileau; Christine Brezden-Masley; Stephen Chia; Susan Dent; Karen Gelmon; Alexander Paterson; Daniel Rayson; Donald A Berry
Journal:  JAMA Oncol       Date:  2016-06-01       Impact factor: 31.777

4.  Use of archived specimens in evaluation of prognostic and predictive biomarkers.

Authors:  Richard M Simon; Soonmyung Paik; Daniel F Hayes
Journal:  J Natl Cancer Inst       Date:  2009-10-08       Impact factor: 13.506

5.  Power estimation in biomarker studies where events are already observed.

Authors:  Mei-Yin C Polley
Journal:  Clin Trials       Date:  2017-08-04       Impact factor: 2.486

6.  Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected].

Authors:  B Peterson; S L George
Journal:  Control Clin Trials       Date:  1993-12

7.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

Authors:  Gunter von Minckwitz; Michael Untch; Jens-Uwe Blohmer; Serban D Costa; Holger Eidtmann; Peter A Fasching; Bernd Gerber; Wolfgang Eiermann; Jörn Hilfrich; Jens Huober; Christian Jackisch; Manfred Kaufmann; Gottfried E Konecny; Carsten Denkert; Valentina Nekljudova; Keyur Mehta; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2012-04-16       Impact factor: 44.544

8.  Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer.

Authors:  Nuria Chic; Stephen J Luen; Paolo Nuciforo; Roberto Salgado; Debora Fumagalli; Florentine Hilbers; Yingbo Wang; Evandro de Azambuja; István Láng; Serena Di Cosimo; Cristina Saura; Jens Huober; Aleix Prat; Sherene Loi
Journal:  J Natl Cancer Inst       Date:  2022-03-08       Impact factor: 13.506

Review 9.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Authors:  Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz
Journal:  Lancet       Date:  2014-02-14       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.